{"id":28428,"date":"2022-10-31T11:45:24","date_gmt":"2022-10-31T11:45:24","guid":{"rendered":"https:\/\/news.cancerresearchuk.org\/?p=24793"},"modified":"2024-11-03T15:13:13","modified_gmt":"2024-11-03T15:13:13","slug":"6-highlights-from-our-black-in-cancer-conference","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/6-highlights-from-our-black-in-cancer-conference\/","title":{"rendered":"6 highlights from our Black in Cancer conference"},"content":{"rendered":"
\"BlackBlack in Cancer co-founders Dr Henry Henderson and Sigourney Bonner. (Photo by John Nicholson)<\/p>\n

” data-medium-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Henry-Henderson-and-Sigourney-Bonner-on-stage-300×168.jpg” data-large-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Henry-Henderson-and-Sigourney-Bonner-on-stage.jpg”><\/p>\n

Black in Cancer co-founders Dr Henry Henderson and Sigourney Bonner. (Photo by John Nicholson)<\/p>\n<\/div>\n

Dr Faith Uwadiae spent 10 years studying science at some of London\u2019s top universities and research institutes before she had the chance to attend a lecture by another Black woman. That lecture wasn\u2019t actually about science, though. It took another year before Uwadiae found a teacher <\/span>in her field that she could identify with, a teacher that looked like her. <\/span> <\/span><\/p>\n

Dr Faith Uwadiae (Photo by John Nicholson)<\/p>\n

” data-medium-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Faith-Uwadiae-at-the-BiC-conference-1-185×300.jpg” data-large-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Faith-Uwadiae-at-the-BiC-conference-1.jpg” class=”wp-image-24806 size-medium” src=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Faith-Uwadiae-at-the-BiC-conference-1-185×300.jpg” alt=”Dr Faith Uwadiae presenting at the Black in Cancer conference” width=”185″ height=”300″ srcset=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Faith-Uwadiae-at-the-BiC-conference-1-185×300.jpg 185w, https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Faith-Uwadiae-at-the-BiC-conference-1-150×244.jpg 150w, https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Faith-Uwadiae-at-the-BiC-conference-1.jpg 200w” sizes=”(max-width: 185px) 100vw, 185px”><\/p>\n

Dr Faith Uwadiae (Photo by John Nicholson)<\/p>\n<\/div>\n

There were many stories like Uwadiae\u2019s at our inaugural Black in Cancer conference, held in partnership with <\/span>Black in Cancer<\/span><\/a> at London\u2019s Science Museum on 10-11 October. <\/span> <\/span><\/p>\n

\u201cI don\u2019t subscribe to the idea that you can\u2019t be what you can\u2019t see,\u201d said Uwadiae, who now works at the Wellcome Trust. \u201cYou can do it. It\u2019s just so much harder.\u201d<\/span><\/p>\n

The conference itself provided plenty of evidence that people can succeed despite adversity. It brought together more than 200 leading cancer researchers, medical professionals and people affected by cancer, primarily from the UK, the US and Canada. They came to make sure things never <\/span>have to be so difficult again. <\/span> <\/span><\/p>\n

\u201cCancer is a very, very heterogeneous disease,\u201d said Black in Cancer co-founder Dr Henry Henderson, a researcher at Tennessee\u2019s Vanderbilt University Medical Centre, at the start of the <\/span>conference. \u201cThe workforce has to be just as different, just as diverse, for us to make tremendous change.\u201d<\/span> <\/span><\/p>\n

We\u2019re partnering with Black in Cancer<\/a> to help make the cancer research community \u2013 and the research we fund \u2013 more inclusive and representative<\/a>. Uwadiae and other attendees are doing the same where they work. But, as the conference showed, that\u2019s just the beginning.<\/p>\n

So, what could \u2018tremendous change\u2019 look like? And why is it so desperately needed?<\/p>\n

Here are 6 of the most important things we learned at the Black in Cancer conference.<\/span> <\/span><\/p>\n

1. Research needs to be more representative<\/span> <\/span><\/h2>\n

If we want to get better at understanding, preventing and treating cancer, we need to consider the people it affects, in all their variety. That\u2019s not happening today. <\/span> <\/span><\/p>\n

Take the <\/span>International Cancer Genome Consortium<\/span><\/a>, which is trying to work out the causes of 50 of the most important cancer types. <\/span> <\/span><\/p>\n

It\u2019s one of the biggest and most ambitious medical research efforts since the Human Genome Project, and it involves countries from around the world. But, as Dr Iain Foulkes, our executive director of research and strategy, told the audience, there\u2019s a \u201cmissing continent\u201d. None of the 25,000 samples collected for the study came from Africa.<\/span><\/p>\n

Things aren\u2019t much better within individual countries. Foulkes also highlighted a study that found <\/span>only 1% of participants in US melanoma, breast and lung cancer clinical trials<\/span><\/a> carried out between 2015 and 2017 could be confirmed as African American. Most of those trials didn\u2019t record any data about race or ethnicity at all.<\/span> <\/span><\/p>\n

That\u2019s a problem. \u201cAs humans, we are complex beings, with multiple diseases, generations and ancestries,\u201d said Foulkes. \u201cThis all adds up in how we respond to different treatments, how our diseases develop, and so forth. And if we\u2019re not analysing that diversity, we\u2019re never really going to make the breakthroughs that we need to see for personalised cancer medicine.\u201d<\/span> <\/span><\/p>\n

2. Cancer cells are being cornered<\/span> <\/span><\/h2>\n

But there are still people driving our understanding of cancer forward. Dr Christina Towers, an assistant professor at the Salk Institute for Biological Studies in California, is one of them. <\/span> <\/span><\/p>\n

Towers is working to target hard-to-treat cancers that start in the pancreas and lungs. Her main approach is to stop cancer cells from recycling their waste products into new energy. <\/span> <\/span><\/p>\n

Blocking the primary recycling process in tumours kills cancer cells by clogging them with waste and starving them of nutrients. It\u2019s a powerful technique that can shrink cancers very quickly, but the evidence for how well it works in practice is mixed.<\/span> <\/span><\/p>\n

That\u2019s the problem Towers is working to solve. She and her team have shown that blocking this recycling process doesn\u2019t shut everything down. It\u2019s more like closing a city\u2019s busiest stretch of motorway. <\/span> <\/span><\/p>\n

A graphic showing a cancer cell as if it were a city.<\/p>\n

” data-image-caption=”<\/p>\n

\u00a9Dr Christina Towers<\/p>\n

” data-medium-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Christie-Towers-cancer-cell-animation.jpg” data-large-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Christie-Towers-cancer-cell-animation.jpg” loading=”lazy” class=”wp-image-24803 size-full” src=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Christie-Towers-cancer-cell-animation.jpg” alt=”A metaphorical graphic showing a cell with roads going through it” width=”200″ height=”200″ srcset=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Christie-Towers-cancer-cell-animation.jpg 200w, https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Christie-Towers-cancer-cell-animation-150×150.jpg 150w, https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Christie-Towers-cancer-cell-animation-96×96.jpg 96w” sizes=”(max-width: 200px) 100vw, 200px”><\/p>\n

Dr Towers compared key processes in cancer cells to road networks in major cities. \u00a9Dr Christina Towers<\/p>\n<\/div>\n

In the short term, traffic grinds to a halt. <\/span><\/p>\n

\u201cThe vast majority of the cells die,\u201d Towers explained. But a few are more cunning. <\/span> <\/span><\/p>\n

\u201cIf you\u2019re sitting in traffic, what are you going to do?\u201d Towers continued. \u201cYou\u2019re going to ask Google to reroute you.\u201d Similarly, some cells are able to work out detours that also allow them to clear out waste and create energy. That allows them to take over. As a result, \u201cthe tumours come back, and our patients are relapsing and back in the clinic\u201d.<\/span> <\/span><\/p>\n

Towers and her team are tracking the detours so they can stop that happening. Already, they\u2019ve found that some cells can bypass the recycling process by joining damaged \u201cenergy powerhouses\u201d, or mitochondria, <\/span>with healthy ones<\/span><\/a> to keep everything running smoothly. <\/span> <\/span><\/p>\n

The Towers lab is also the one of the first to uncover a clue about why our cells contain tiny, mysterious packages called \u2018mitochondrial-derived vesicles\u2019 (MDVs). <\/span> <\/span><\/p>\n

In cells that survive after the main recycling process is blocked, the number of MDVs starts to increase. It turns out that they can work like robotic vacuum cleaners, wrapping up damaged portions of mitochondria and taking them to other parts of the cell that can also dispose of waste.<\/span> <\/span><\/p>\n

Importantly, both of those processes could also be disrupted by specific drugs. If Towers and her team can find all the detours \u2013 and design drugs that can block them \u2013 they have a chance to improve outcomes for many people with lung and pancreatic cancers. <\/span> <\/span><\/p>\n

3. Who gets the best?<\/span> <\/span><\/h2>\n

Creating effective treatments is only the first step. No drug can make a difference if it doesn\u2019t reach the people who need it. That takes extra effort.<\/span> <\/span><\/p>\n

Dr Brandon Blue (Photo by John Nicholson)<\/p>\n

” data-medium-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Brandon-Blue-at-the-Black-in-Cancer-conference.jpg” data-large-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Brandon-Blue-at-the-Black-in-Cancer-conference.jpg” loading=”lazy” class=”wp-image-24802 size-full” src=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Brandon-Blue-at-the-Black-in-Cancer-conference.jpg” alt=”Dr Brandon Blue presenting at the Black in Cancer conference” width=”200″ height=”200″ srcset=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Brandon-Blue-at-the-Black-in-Cancer-conference.jpg 200w, https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Brandon-Blue-at-the-Black-in-Cancer-conference-150×150.jpg 150w, https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Brandon-Blue-at-the-Black-in-Cancer-conference-96×96.jpg 96w” sizes=”(max-width: 200px) 100vw, 200px”><\/p>\n

Dr Brandon Blue (Photo by John Nicholson)<\/p>\n<\/div>\n

Dr Brandon Blue is an oncologist specialising in <\/span>blood cancers<\/span><\/a> at Florida\u2019s Moffitt Cancer Centre, one of the <\/span>leading cancer centres in the US. He\u2019s seen just how effective <\/span>CAR T-cell therapies<\/span><\/a>, which train the body\u2019s immune system to target cancer cells the way it does viruses and bacteria, can be for people affected by cancers that don\u2019t form solid tumours. He\u2019s also noticed disparities in who gets them.<\/span><\/p>\n

\u201cWe probably do more CAR T than most places in the world,\u201d he explained. \u201cAnd I noticed a trend: there are no Black people getting it.<\/span> <\/span><\/p>\n

\u201cI was confused. There are certain diseases, such as diffuse large B-cell lymphoma, where, unfortunately, African American patients actually do the worst. And so I said, \u2018Here\u2019s a game-changer for this disease that\u2019s killing Black people \u2013 where they at?\u2019\u201d <\/span> <\/span><\/p>\n

None of the other US cancer centres Blue contacted had any answers. If anything, they hadn\u2019t realised there was a question. There was no race or ethnicity information in their CAR T-cell therapy patient databases. <\/span><\/p>\n

Blue suggested they change that (they\u2019ve now done so). Then, he talked to Florida\u2019s oncologists. <\/span> <\/span><\/p>\n

It turned out that the doctors that knew the least about CAR T-cell therapies were also the least likely to offer it to patients. And those doctors happened to work in the areas with the largest African American populations.<\/span> <\/span><\/p>\n

It\u2019s an example of how social and structural factors contribute to cancer outcomes. Encouragingly, it\u2019s also something that can be addressed with education.<\/span> <\/span><\/p>\n

It\u2019s not the only thing. Researchers can also learn by listening to patients. Later in the conference, Dr Tanimola Martins from the University of Exeter explained how he began his headline-grabbing research into <\/span>racial disparities in NHS cancer waiting times<\/span><\/a> after hearing personal stories told at events for families affected by cancer. <\/span> <\/span><\/p>\n

This is about visibility, too.<\/span><\/p>\n

Right now, it takes openness and creativity to even spot the problems that need our attention, let alone solve them. \u201cThere is no cookie-cutter answer,\u201d said Blue. <\/span><\/p>\n

But there is a way to ask the question. <\/span> <\/span><\/p>\n

\u201cWe\u2019ve got to bring it to the people.\u201d <\/span> <\/span><\/p>\n

4. Clich\u00e9s don\u2019t help<\/span> <\/span><\/h2>\n

When Ricki Fairley received the phone call telling her she had triple negative breast cancer, she didn\u2019t have the time to be ill. She was running an advertising business. She had a plane to catch. <\/span> <\/span><\/p>\n

After actress Victoria Ekanoye got her breast cancer diagnosis \u2013 which only came because she pushed for a second and then a third opinion \u2013 she had to compose herself, step in front of the cameras, and pretend to be someone else. <\/span><\/p>\n

Stories like these, both of which were told at the conference, might bring a clich\u00e9 to mind. Concluding her keynote, Dawn Butler, MP, who received her own breast cancer diagnosis alone in a London hospital during COVID-19, questioned it.<\/span> <\/span><\/p>\n

Dawn Butler, MP (Photo by John Nicholson)<\/p>\n

” data-medium-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/MP-Dawn-Butler-at-the-Black-in-Cancer-conference-185×300.jpg” data-large-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/MP-Dawn-Butler-at-the-Black-in-Cancer-conference.jpg” loading=”lazy” class=”wp-image-24807 size-medium” src=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/MP-Dawn-Butler-at-the-Black-in-Cancer-conference-185×300.jpg” alt=”Dawn Butler, MP, speaking at the Black in Cancer conference” width=”185″ height=”300″ srcset=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/MP-Dawn-Butler-at-the-Black-in-Cancer-conference-185×300.jpg 185w, https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/MP-Dawn-Butler-at-the-Black-in-Cancer-conference-150×244.jpg 150w, https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/MP-Dawn-Butler-at-the-Black-in-Cancer-conference.jpg 200w” sizes=”(max-width: 185px) 100vw, 185px”><\/p>\n

Dawn Butler, MP (Photo by John Nicholson)<\/p>\n<\/div>\n

\u201cI want to end on \u2018strong Black women\u2019,\u201d she said. \u201cI don\u2019t hate the term, but I\u2019m very mindful of it. It\u2019s often said in a way that implies that Black women can take the punches, that they can take the criticisms and the licks because they\u2019re strong \u2013 but other women you need to treat more gently, more caringly, because they are delicate and precious.\u201d<\/span> <\/span><\/p>\n

This isn\u2019t just about words. Butler\u2019s concern is that the way society talks about Black women negatively impacts their health outcomes. <\/span> <\/span><\/p>\n

\u201cBlack women are less likely <\/a><\/span>to go for a mammogram<\/span><\/a> when invited by the NHS, and they are [nearly] <\/a><\/span>twice as likely<\/a> to present with advanced [stage 3 or 4] breast cancer than white women,\u201d she stressed.<\/span> <\/span><\/p>\n

\u201cThere are many reasons for this. But one of those reasons is because sometimes Black women are not taken seriously when they raise issues, especially about their health.\u201d<\/span> <\/span><\/p>\n

At that point, the clich\u00e9s get less flattering. As Butler also pointed out, it\u2019s all too easy for \u2018strong Black woman\u2019 to become \u2018angry Black woman\u2019. \u201cBut it\u2019s not about anger. It\u2019s often about frustration. It\u2019s just another battle that we don\u2019t really want to fight.\u201d <\/span> <\/span><\/p>\n

\n

Black men in England are <\/span><\/i>twice as likely<\/span><\/i><\/a> to be diagnosed with prostate cancer as white men. They are also twice as likely to die from the disease.<\/span><\/i> <\/span><\/p>\n

In the US, Black women are less likely to be diagnosed with breast cancer than white women. Even so, they are <\/span><\/i>40% more likely<\/span><\/i><\/a> to die from it. <\/span><\/i> <\/span><\/p>\n<\/div>\n

5. How to make a difference<\/span> <\/span><\/h2>\n

No one affected by cancer should have to be \u2018stronger\u2019 than anyone else. Everyone should receive the same quality of care. <\/span> <\/span><\/p>\n

Sometimes, that means treating their cancers differently. <\/span> <\/span><\/p>\n

For one thing, large-scale studies have shown that some cancer drugs work differently, and even cause different side effects, in people of Asian origin than in white Europeans. <\/span> <\/span><\/p>\n

And, although there are relatively few Ashkenazi Jewish people in the US, research has shown that they are around 10 times more likely to have a potentially cancer-causing mutation in a tumour suppressing <\/span>BRCA<\/span><\/a> gene than the general population. <\/span> <\/span><\/p>\n

So, when a person of Ashkenazi Jewish descent visits Dr Fiyinfolu Balogun\u2019s clinic in New York, he knows what tests to order. If they are diagnosed with cancer because of a BRCA mutation, he also knows the best drugs to prescribe. <\/span> <\/span><\/p>\n

We have the ability and expertise to improve cancer outcomes for everyone. We just need to learn how to apply it more broadly.<\/span> <\/span><\/p>\n

Ricki Fairley is now the chief executive of US charity <\/span>TOUCH<\/span>, the Black Breast Cancer Alliance<\/span><\/a>. By defining Black breast cancer as a unique disease and focusing on the specific social, historical and biological factors that set it apart, she\u2019s mapping out a way to lessen its burden.<\/span> <\/span><\/p>\n

As part of their <\/span>When We Tri(al)<\/span><\/a> initiative, Fairley and her colleagues explain clinical trials to Black women on their own terms, as caring \u2018Breasties\u2019 rather than representatives of faceless medical institutions. It\u2019s working. <\/span> <\/span><\/p>\n

\u201cI realised very quickly that I could get people from \u2018I\u2019ll never do a trial\u2019 to \u2018Sign me up tomorrow\u2019 in 5 minutes,\u201d she said. <\/span> <\/span><\/p>\n

In a matter of months, TOUCH has been able to recruit around 4,000 Black women to take part in clinical trials for breast cancer treatments in the US. <\/span> <\/span><\/p>\n

That\u2019s not all. Dr Fiyinfolu and Dr Onyinye Balogun, among others, are running trials with patients across North America and Africa to better understand how Black people\u2019s physiology impacts how their cancers develop and respond to treatments.<\/span> <\/span><\/p>\n

Closer to home, at the Brooklyn Methodist Hospital, Onyinye Balogun and her colleagues have made breast cancer trial participation more representative simply by making it routine practice to tell people affected by cancer what trials they are eligible for. The same technique has increased recruitment rates in all patient groups. <\/span> <\/span><\/p>\n

\u201cWhen you improve things for minoritised populations,\u201d she said, \u201cthings get better for everyone.\u201d<\/span> <\/span><\/p>\n

6. The difference we can make<\/span> <\/span><\/h2>\n
Alfred Samuels (Photo by John Nicholson)<\/p>\n

” data-medium-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Alfred-Samuels-at-the-Black-in-Cancer-conference-185×300.jpg” data-large-file=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Alfred-Samuels-at-the-Black-in-Cancer-conference.jpg” loading=”lazy” class=”wp-image-24801 size-medium” src=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Alfred-Samuels-at-the-Black-in-Cancer-conference-185×300.jpg” alt=”Alfred Samuels on stage at the Black in Cancer conference at the” width=”185″ height=”300″ srcset=”https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Alfred-Samuels-at-the-Black-in-Cancer-conference-185×300.jpg 185w, https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Alfred-Samuels-at-the-Black-in-Cancer-conference-150×244.jpg 150w, https:\/\/news.cancerresearchuk.org\/wp-content\/uploads\/2022\/10\/Alfred-Samuels-at-the-Black-in-Cancer-conference.jpg 200w” sizes=”(max-width: 185px) 100vw, 185px”><\/p>\n

Alfred Samuels (Photo by John Nicholson)<\/p>\n<\/div>\n

Ultimately, more representative trials mean more people like <\/span>Alfred Samuels<\/span><\/a>, who joined the <\/span>STAMPEDE trial<\/span><\/a> after he was diagnosed with advanced metastatic prostate cancer in 2012.<\/span><\/p>\n

\u201cI stand here before you today the result of a man that got onto a clinical trial, which was funded by Cancer Research UK,\u201d he said. \u201cThey saved my life \u2013 without a doubt.\u201d<\/span> <\/span><\/p>\n

That\u2019s only part of the story. Today he\u2019s an advocate for more diverse and inclusive clinical trials, but Alfred remembers when he didn\u2019t want to join one.<\/span> <\/span><\/p>\n

\u201cMy head was elsewhere. I\u2019d given up. I\u2019d resigned myself to the fact I was going to die.\u201d <\/span> <\/span><\/p>\n

It was his wife, Grace, who helped him realise why he should sign up for STAMPEDE.<\/span> <\/span><\/p>\n

Grace, a former nurse, was in the audience as Alfred spoke. She has supported him through every step of his treatment. They even wrote Alfred\u2019s speech together. But this part wasn\u2019t in the script.<\/span> <\/span><\/p>\n

Alfred pointed to Grace.<\/span> <\/span><\/p>\n

\u201cLadies and gentlemen, trust me when I say that she, and Cancer Research UK, saved my life.<\/span> <\/span><\/p>\n

\u201cIt was tough. It was more than tough. But my lady stood beside me. She pushed me to live. She made sure that her man was not going to die.\u201d<\/span> <\/span><\/p>\n

At the end of the conference, Black in Cancer co-founder Sigourney Bonner, a researcher at the Cancer Research UK Cambridge Institute, urged everyone to remember the stories they had heard.<\/span> <\/span><\/p>\n

Alfred explained why. \u201cWe all love someone,\u201d he said. \u201cWe don\u2019t want that loved one to die, regardless of race, ethnicity, or otherwise.\u201d<\/span> <\/span><\/p>\n

Tim<\/em><\/p>\n

More on this topic<\/h3>\n<\/p>\n

Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Dr Faith Uwadiae (Photo by John Nicholson) There were many stories like Uwadiae\u2019s at our inaugural Black in Cancer conference, held in partnership with Black in Cancer at London\u2019s Science Museum on 10-11 October. \u201cI don\u2019t subscribe to the idea that you can\u2019t be what you can\u2019t see,\u201d said Uwadiae, who now works at the […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-28428","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/28428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=28428"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/28428\/revisions"}],"predecessor-version":[{"id":43164,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/28428\/revisions\/43164"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=28428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=28428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=28428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}